Natalizumab reduced serum levels of neurofilament light chain in secondary progressive multiple sclerosis patients from the phase 3 ASCEND study

被引：0
|
作者：
Kapoor, R. [1 ]
Sellebjerg, F. [2 ]
Hartung, H. -P. [3 ]
Arnold, D. L. [4 ]
Freedman, M. S. [5 ]
Jeffery, D. [6 ]
Miller, A. [7 ]
Edwards, K. R. [8 ]
Singh, C. M. [9 ]
Chang, I. [9 ]
Ren, Z. [9 ]
Sangurdekar, D. [9 ]
Zhu, B. [9 ]
Sheikh, S. [9 ]
Mehta, D. [9 ]
Ho, P. -R. [9 ]
Campbell, N. [9 ]
Edwards, M. [9 ]
Fisher, E. [9 ]
Kieseier, B. C. [9 ]
Rudick, R. A. [9 ]
Plavina, T. [9 ]
机构：
[1] UCL Inst Neurol, London, England
[2] Univ Copenhagen, Danish Multiple Sclerosis Ctr, Rigshosp, Copenhagen, Denmark
[3] Heinrich Heine Univ, Med Fac, Dept Neurol, Dusseldorf, Germany
[4] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada
[5] Univ Ottawa, Ottawa Hosp, Res Inst, Ottawa, ON, Canada
[6] Piedmont HealthCare, Mooresville, NC USA
[7] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[8] MS Ctr Northeastern New York, Latham, NY USA
[9] Biogen, Cambridge, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1740
引用
下载
收藏
页码：988 / 988
页数：1
相关论文
共 50 条
  • [11] Dynamic of neurofilament light chains after cessation of natalizumab in patients with relapsing remitting and secondary progressive multiple sclerosis
    Proschmann, U.
    Akguen, K.
    Ziemssen, T.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 482 - 482
  • [12] Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
    Fissolo, Nicolas
    Pignolet, Beatrice
    Rio, Jordi
    Vermersch, Patrick
    Ruet, Aurelie
    deSeze, Jerome
    Labauge, Pierre
    Vukusic, Sandra
    Papeix, Caroline
    Martinez-Almoyna, Laurent
    Tourbah, Ayman
    Clavelou, Pierre
    Moreau, Thibault
    Pelletier, Jean
    Lebrun-Frenay, Christine
    Bourre, Bertrand
    Defer, Gilles
    Montalban, Xavier
    Brassat, David
    Comabella, Manuel
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (04):
  • [13] Serum neurofilament light chain levels predict long-term disability progression in patients with progressive multiple sclerosis
    Comabella, Manuel
    Sastre-Garriga, Jaume
    Carbonell-Mirabent, Pere
    Fissolo, Nicolas
    Tur, Carmen
    Malhotra, Sunny
    Pareto, Deborah
    Aymerich, Francesc X.
    Rio, Jordi
    Rovira, Alex
    Tintore, Mar
    Montalban, Xavier
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (07): : 732 - 740
  • [14] Renal function influences serum neurofilament light chain levels in patients with multiple sclerosis
    Gasque Rubio, R.
    Cubas Nunez, L.
    Castillo Villalba, J.
    Carratala Bosca, S.
    Alcala, C.
    Perez Miralles, F.
    Quintanilla Bordas, C.
    Laiz Marro, B.
    Casanova Estruch, B.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 585 - 585
  • [15] Serum Neurofilament Light Chain Levels as a Biomarker of Disease Activity and Treatment Response in Patients with Progressive and Relapsing Multiple Sclerosis
    Pedrini, Marzena
    Kaskow, Belinda
    Trend, Stephanie
    Carroll, William
    Walters, Susan
    Maceski, Aleksandra
    Kuhle, Jens
    Kermode, Allan
    NEUROLOGY, 2023, 100 (17)
  • [16] Neurofilament Light Chain Levels In Pregnant Multiple Sclerosis Patients
    Pablo Cuello, Juan
    Martinez Gines, Maria Luisa
    Kuhle, Jens
    Garcia Dominguez, Jose Manuel
    Lozano Ros, Alberto
    Romero Delgado, Fernando
    Higueras, Yolanda
    Meldana Rivera, Ariana
    Goicochea Briceno, Haydee
    Garcia Tizon, Santiago
    de-Leon Ruiz, Juan
    Alvarez Lafuente, Roberto
    Inmaculada Dominguez-Mozo, Maria
    Perez-Perez, Silvia
    Heras, Silvia Medina
    Velasco, Jose Ignacio Fernandez
    Tejeda-Velarde, Amalia
    De Andres, Clara
    Villar, Luisa Maria
    NEUROLOGY, 2019, 92 (15)
  • [17] ASCEND study of natalizumab efficacy on reducing disability in patients with secondary progressive multiple sclerosis: baseline demographics and disease characteristics
    Mikol, D.
    Freedman, M. S.
    Goldman, M. D.
    Hartung, H-P
    Havrdova, E.
    Jeffery, D.
    Kapoor, R.
    Miller, A.
    Sellebjerg, F.
    Lee, S.
    Chen, Y.
    Cadavid, D.
    Ticho, B.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 507 - 508
  • [18] ASCEND Study of Natalizumab Efficacy on Disability in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Baseline Demographics and Disease Characteristics
    Mikol, Daniel
    Freedman, Mark S.
    Goldman, Myla D.
    Hartung, Hans-Peter
    Havrdova, Eva
    Jeffery, Douglas
    Kapoor, Raj
    Miller, Aaron
    Sellebjerg, Finn
    Lee, Sophia
    Chen, Yun
    Cadavid, Diego
    Ticho, Barry
    ANNALS OF NEUROLOGY, 2013, 74 : S59 - S60
  • [19] Effect of natalizumab on disability progression in patients with non-active secondary progressive multiple sclerosis in ASCEND
    Chen, Z.
    Gafson, A.
    Belachew, S.
    Riester, K.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 214 - 215
  • [20] Serum-Neurofilament light chain levels in secondary progressive multiple sclerosis are associated with grey matter destruction characterized by relaxation rates
    Schneider, Ruth
    Ladopoulos, Theodoros
    Bellenberg, Barbara
    Beyer, Leon
    Faissner, Simon
    Gold, Ralf
    Gerwert, Klaus
    Lukas, Carsten
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 283 - 284
12345